ArticleWorld journal of oncology2025
Utility of Alpha-Fetoprotein and Protein Induced by Vitamin K Absence or Antagonist-II Kinetics in Predicting Radiologic Response and Survival in Unresectable Hepatocellular Carcinoma Undergoing Immunotherapy.
Article in World journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alpha-fetoprotein (AFP) is currently the most commonly used biomarker for hepatocellular carcinoma (HCC) surveillance. However, protein induced by vitamin K absence or antagonist-II (PIVKA-II) may have a better prognostic role in some patients. The aim of this study was to investigate the prognostic roles of AFP and PIVKA-II kinetic changes in predicting outcomes in patients with unresectable HCC receiving immunotherapy. Methods: Data were collected from subjects with Child-Pugh class A, and Barcelona Clinic Liver Cancer (BCLC) stage B or C HCC, who received immunotherapy from September 2021 to June 2023. The exclusion criteria included cases with normal values of AFP or PIVKA-II. The values of AFP and PIVKA-II at baseline and 4 weeks after initiation of therapy were recorded. The clinical baseline characteristics, and therapeutic outcomes, including radiologic objective response (OR) and overall survival (OS) of enrolled patients were collected and further analyzed. Results: Among the 33 enrolled patients, 10 and 23 cases achieved OR and non-OR, respectively. A decline in AFP levels of more than 30% from baseline during immunotherapy had the best diagnostic efficacy (0.91) and ideal receiver operating characteristic (ROC) curve (area under the curve (AUC) = 0.907). Combined AFP (≥ 30% decline)/PIVKA (≥ 15% decline) responders had a significantly positive impact on radiologic OR and better OS (hazard ratio (HR): 0.21, 95% confidence interval (CI): 0.06 - 0.73, P = 0.014). Conclusions: The patients with combined AFP/PIVKA-II decline during immunotherapy had a significantly better radiologic response and survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.